“Microdosers” of LSD and magic mushrooms are wiser and more creative. Anderson T., Petranker R. The Conversation, 2018 Available from: http://theconversation.com/microdosers-of-lsd-and-magicmushrooms- are-wiser-and-more-creative-101302 We just ran the first ever pre-registered scientific study on the microdosing of psychedelics and found some very promising results. We compared people who microdose — that is, who take a psychedelic substance such as LSD (lysergic acid diethylamide) or “magic” mushrooms (psilocybin) in very small quantities — with those who don’t, and found that microdosers had healthier scores on key mental health and well-being measures. Specifically, we found that microdosers scored higher on measures of wisdom, open-mindedness and creativity. Microdosers also scored lower on measures [...]
Lire la suitePsychedelic microdosing benefits and challenges : an empirical codebook Thomas Anderson, Rotem Petranker2, Adam Christopher, Daniel Rosenbaum, Cory Weissman, Le-Anh Dinh-Williams, Katrina Hui and Emma Hapke Harm Reduction Journal, 2019, 16, 43, 1-10 https://doi.org/10.1186/s12954-019-0308-4 Abstract Background : Microdosing psychedelics is the practice of consuming very low, sub-hallucinogenic doses of a psychedelic substance, such as lysergic acid diethylamide (LSD) or psilocybin-containing mushrooms. According to media reports, microdosing has grown in popularity, yet the scientific literature contains minimal research on this practice. There has been limited reporting on adverse events associated with microdosing, and the experiences of microdosers in community samples have not been categorized. Methods : In the [...]
Lire la suitePsychedelics in the treatment of unipolar mood disorders : a systematic review James J.H. Rucker, Luke A. Jelen, Sarah Flynn, Kyle D. Frowde and Allan H. Young Journal of Psychopharmacology, 2016, 1-10 DOI: 10.1177/0269881116679368 Abstract Unipolar mood disorders, including major depressive disorder and persistent depressive disorder (dysthymia), confer high rates of disability and mortality and a very high socioeconomic burden. Current treatment is suboptimal in most cases and there is little of note in the pharmaceutical development pipeline. The psychedelic drugs, including lysergic acid diethylamide and psilocybin, were used extensively in the treatment of mood disorders, and other psychiatric conditions, before their prohibition in the [...]
Lire la suiteAssociations between adolescent cannabis use frequency and adult brain structure : A prospective study of boys followed to adulthood. Madeline H. Meier, Roberta A. Schriber, Jordan Beardslee, Jamie Hanson, Dustin Pardini Drug and Alcohol Dependence, 2019, 202, 191-199 Copyright © 2019. Published by Elsevier B.V. PMID : 31357120 DOI : 10.1016/j.drugalcdep.2019.05.012 Abstract BACKGROUND : Few studies have tested the hypothesis that adolescent cannabis users show structural brain alterations in adulthood. The present study tested associations between prospectively-assessed trajectories of adolescent cannabis use and adult brain structure in a sample of boys followed to adulthood. METHODS : Data came from the Pittsburgh Youth Study - a longitudinal [...]
Lire la suiteConsommer du cannabis à l’adolescence n’aurait pas d’impact sur la structure du cerveau à l’âge adulte 31 juillet 2019 Floriane Ramfos © DR La dangerosité du cannabis pour le développement neuronal des adolescents est un argument courant chez les partisans de la prohibition. Pourtant, selon une étude du Drug and Alcohol Dependence, la consommation de cannabis pendant l’adolescence n’est pas associée à des différences structurelles dans le cerveau à l’âge adulte. Méthodologie et résultats L’étude a été réalisée auprès de 1000 hommes, auxquels les chercheurs ont demandé de déclarer leur consommation de cannabis lorsqu’ils avaient entre 13 à 19 ans. Cela a permis aux scientifiques d’identifier différentes [...]
Lire la suiteIntroduction, 24e Journées du RESPADD "Usages thérapeutiques des cannabinoïdes", Session du GRECC, Docteur Christian Sueur, 26 juin 2019, Paris Bonjour Bienvenu à toutes et à tous Merci d’être venus aussi nombreux à ce premier colloque co-organisé par le GRECC et le RESPADD sur le thème du Cannabis Thérapeutique, ou, de façon « dépassionnée », sur les Usages Cliniques des Cannabinoïdes. Je veux tout d’abord remercier Nicolas Bonnet, Anne Borgne et le RESPADD de nous avoir invité à leur colloque annuel, de nous avoir donné offert cette première demie journée, et d’avoir invité de nombreux intervenants que nous avons proposés pour ces 2 jours de rencontres cannabiques. Le GRECC (Groupe de [...]
Lire la suiteEfficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study Carla M. Canuso, M.D., Jaskaran B. Singh, M.D., Maggie Fedgchin, Pharm.D., Larry Alphs, M.D., Ph.D., Rosanne Lane, M.A.S., Pilar Lim, Ph.D., Christine Pinter, M.S., David Hough, M.D., Gerard Sanacora, M.D., Ph.D., Husseini Manji, M.D., Wayne C. Drevets, M.D. American Journal of Psychiatry, 2018, 175, 620–630 doi: 10.1176/appi.ajp.2018.17060720 Objective : The authors compared the efficacy of standardof- care treatment plus intranasal esketamine or placebo for rapid reduction of symptoms of major depression, including suicidality, among [...]
Lire la suiteTexas Peyote Culture Kevin FEENEY Cactus and Succulent Journal, 2018, 90, (1), 29-38 Peyote (Lophophora williamsii (Lem.) Coult.) has deep roots in Texas, or a deep taproot to be precise. While Texas is currently home to a federally regulated peyote trade, where members of the Native American Church (NAC) can legally purchase peyote for use in religious ceremonies, archaeological sites in Texas, and neighboring Coahuila, also mark the earliest known ceremonial associations between humans and peyote. It is believed that the peyote rituals of the Huichol, Nahua, Tarahumara, Cora, Tepehuan, and more recently the NAC, all trace their origins to the peyote gardens [...]
Lire la suiteThe paradoxical psychological effects of lysergic acid diethylamide (LSD) R. L. Carhart-Harris, M. Kaelen, M. Bolstridge, T. M. Williams, L. T. Williams, R. Underwood, A. Feilding and D. J. Nutt Psychological Medicine, 2016, 46, 1379–1390. doi:10.1017/S0033291715002901 Background : Lysergic acid diethylamide (LSD) is a potent serotonergic hallucinogen or psychedelic that modulates consciousness in a marked and novel way. This study sought to examine the acute and mid-term psychological effects of LSD in a controlled study. Method : A total of 20 healthy volunteers participated in this within-subjects study. Participants received LSD (75 μg, intravenously) on one occasion and placebo (saline, intravenously) on another, in a [...]
Lire la suitePsychedelic Drugs in Biomedicine Evan J. KYZAR, Charles D. NICHOLS, Paul R. GAINETDINOV, David E. NICHOLS, Allan V. KALUEFF Trends in Pharmacological Sciences, 2017, 38, (1), 992-1005 https://doi.org/10.1016/j.tips.2017.08.003 Trends Psychedelic drugs profoundly alter human behavior, acting primarily via agonism at the 5-HT2A receptor in the brain. Research into the mechanisms of psychedelic drugs is experiencing a renaissance after years of stagnation. Animal models show that psychedelic drugs alter a number of crucial molecular mechanisms. Psychedelic drugs cause widespread changes in cognition and brain connectivity. Recent pilot studies show LSD and psilocybin are effective in treating psychiatric disorders and possibly other illnesses. Psychedelic biomedicine is rapidly emerging as an important area [...]
Lire la suite